Therapeutics Initiative |

13 Nov [159] Escitalopram vs. citalopram: one enantiomer’s dominance reflects marketing, not evidence

Posted at 06:00h in Therapeutics Letter 0 Comments

Jump to: Abstract | Full Text | Plain Language Summary | Conclusions | References Plain Language Summary Escitalopram vs. citalopram: one enantiomer’s dominance reflects marketing, not evidence What is this research about? This research looks at two drugs, escitalopram...

13 Nov TI Blog Update: November 2025

Posted at 11:47h in Blog 0 Comments

We are excited to announce that today, we posted Therapeutics Letter 159, a detailed re-evaluation of how the single enantiomer escitalopram (Cipralex, Lexapro) compares with its parent drug, citalopram (Celexa). In 2002 we first reported...

November 2025

13 Nov [159] Escitalopram vs. citalopram: one enantiomer’s dominance reflects marketing, not evidence

13 Nov TI Blog Update: November 2025

Contact

Subscribe for Updates